{"entity":{"id":"paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024","kind":"paper","name":"CONTINUUM: induction-concurrent chemoradiotherapy with or without sintilimab in locoregionally advanced nasopharyngeal carcinoma","aka":[],"tldr":"Adding the PD-1 antibody sintilimab to chemotherapy and radiotherapy for advanced, non-metastatic nasopharyngeal cancer raised three-year event-free survival from 76 to 86 percent, with more but manageable side effects.","summary":"Multicentre open-label randomised phase 3 trial at nine hospitals in China: 425 adults with high-risk stage III to IVa nasopharyngeal carcinoma were randomised to gemcitabine-cisplatin induction and concurrent cisplatin radiotherapy with (210) or without (215) 12 cycles of sintilimab.\n\nAt a median follow-up of 41.9 months, three-year event-free survival was 86 percent with sintilimab against 76 percent without (stratified hazard ratio 0.59, p 0.019). Grade 3 to 4 adverse events occurred in 74 against 65 percent; grade 3 to 4 immune-related adverse events in 10 percent of the sintilimab group, with two immune-related deaths.","asOf":"2026-09-22","links":[{"label":"Lancet 2024","url":"https://doi.org/10.1016/S0140-6736(24)00594-4"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38824941/"}],"tags":[],"related":[],"cancers":["locoregionally-advanced-nasopharyngeal-carcinoma","nasopharyngeal"],"sections":[],"technologies":[],"targets":[],"drugs":["sintilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["continuum"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00594-4","pmid":"38824941","authors":"Liu X, Zhang Y, Yang KY, et al.","paperType":"rct","findings":["Three-year event-free survival 86 percent (95% CI 81 to 90) versus 76 percent (70 to 81); hazard ratio 0.59 (0.38 to 0.92), p 0.019.","Grade 3 to 4 adverse events 74 versus 65 percent; grade 3 to 4 immune-related events 10 percent with sintilimab."],"whatItMeans":"PD-1 blockade added to chemoradiotherapy is a new option for high-risk locoregionally advanced nasopharyngeal carcinoma; longer follow-up will show whether it lengthens survival.","caveats":["Chinese population with endemic EBV-related disease; open-label; overall survival immature."],"changedPractice":true,"participants":425},"route":"/key-papers/paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024/","neighbours":{"cancer":[{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/"},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"}],"drug":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"trial":[{"id":"continuum","kind":"trial","name":"CONTINUUM","route":"/trials/continuum/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}